Reuters logo
BRIEF-CASI Pharmaceuticals reports on enrollment status of ENMD-2076 phase 2 study in triple-negative breast cancer
April 14, 2017 / 8:55 PM / 8 months ago

BRIEF-CASI Pharmaceuticals reports on enrollment status of ENMD-2076 phase 2 study in triple-negative breast cancer

April 14 (Reuters) - Casi Pharmaceuticals Inc

* Says decision has been reached to stop further patient enrollment in its phase 2, open-label study of enmd-2076

* Company continues to collect and evaluate data in those patients enrolled in study

* Says biomarker program which evaluates potential markers that could be predictive of a response to enmd-2076 is ongoing

* Says ongoing phase 2a study in china in patients with tnbc continues Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below